



AF/1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Let re the Application of: **Cohn et al**

Application No: **09/658,261**

Group Art Unit: **1614**

Filed: **September 8, 2000**

Examiner: **R. J. Henley III**

For: **Methods of Treating and Preventing Congestive Heart Failure with Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate**

Attorney Docket No: **102258.288**

ATTN: BOX AF

Assistant Commissioner of Patents
Washington, DC 20231

RECEIVED

JUL 3 2002

TECH CENTER 1600/2900

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.116

This Response is submitted in reply to the Office Action dated May 21, 2002, for which a response is due on or before August 21, 2002.

Applicants thank the Examiner for indicating that claims 1-38 and 42-49 are in condition for allowance.

No fee is believed to be due; however, the Commissioner is authorized to charge any necessary fees to Deposit Account No. 08-0219 to maintain the pendency of the present application.

Please amend the present application, without prejudice, as follows.

IN THE CLAIMS:

Attached hereto as Appendix 1 is a copy of the pending claims. Attached hereto as Appendix 2 is a copy of the amendments made to the claims.

I. Remarks

After entry of the amendment, claims 1-38, 42-49 and 52-58 are pending.

Claim 32 has been amended to correct a typographical error.

Claims 39-41 and 50 have been cancelled without prejudice. Applicants reserve the right to file divisional applications directed to this subject matter.

09658261
07/11/2002 FPATERS 08000003 080213
36300 CH
01 FC:203

B